证券代码：002370 证券简称：亚太药业 公告编号：2025-086 一、本次协议转让情况概述 浙江亚太药业股份有限公司 关于筹划公司控制权变更事项进展暨受让方股权结构调整 的公告 浙江亚太药业股份有限公司（以下简称"公司"）控股股东宁波 富邦控股集团有限公司（以下简称"富邦集团"）及一致行动人上海 汉贵投资管理有限公司（以下简称"汉贵投资"）于 2025 年 10 月 13 日与浙江星浩控股合伙企业（有限合伙）（以下简称"星浩控股"） 及浙江星宸股权投资合伙企业（有限合伙）（以下简称"星宸投资"） 签署了《股份转让协议》，富邦集团和汉贵投资拟通过协议转让方式 转让公司 14.61%股份，共计 108,945,566 股，转让价格为 8.26 元/ 股，合计总金额为 90,000.00 万元，其中星浩控股受让富邦集团持有 的公司 60,525,314 股股份，星宸投资受让富邦集团、汉贵投资分别 持有的公司 28,894,686 股股份、19,525,566 股股份。本次协议转让 完成后，公司的控股股东将由富邦集团变更为星浩控股，公司的实际 控制人将由宋汉平、傅才、胡铮辉组成的管理团队变更为邱中勋。本 次事项 ...

关于 国联民生证券承销保荐有限公司 浙江亚太药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 （修订稿） 二〇二五年十月 国联民生承销保荐财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露+内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》等法律法规的规定，国联民生证券承销保荐有限公司按照证 券行业公认的业务标准、道德规范和勤勉尽责精神，对本次信息披露义务人披 露的《浙江亚太药业股份有限公司详式权益变动报告书》进行核查，并出具核查 意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《详式权益变动报告书》进行了核查，确信披露文件内容与格式符合规定，并保 证所发表的专业意见与信息披露义务人披露内容不存在实质性差异； 2、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及 时，不存在 ...

Market Overview - The Shanghai Composite Index rose by 0.22% on October 23, with 21 out of 28 sectors experiencing gains. The top-performing sectors were coal and oil & petrochemicals, with increases of 1.75% and 1.53% respectively. Conversely, the telecommunications and real estate sectors saw declines of 1.51% and 0.99% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 33.733 billion yuan across the two markets. Six sectors experienced net inflows, with the coal sector leading at a net inflow of 1.465 billion yuan, followed by the media sector with a net inflow of 362 million yuan [1] - A total of 25 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 5.435 billion yuan, followed by the machinery equipment sector with an outflow of 4.999 billion yuan. Other sectors with significant outflows included pharmaceuticals, telecommunications, and electrical equipment [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector declined by 0.60%, with a net outflow of 4.627 billion yuan. Out of 475 stocks in this sector, 183 stocks rose, 4 stocks hit the daily limit up, and 274 stocks fell [2] - Within the sector, 121 stocks saw net inflows, with five stocks receiving over 30 million yuan in net inflows. The top stock for net inflow was Jianfa Zhixin, with an inflow of 123 million yuan, followed by Sainuo Medical and Mindray Medical with inflows of 121 million yuan and 60.069 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jianfa Zhixin: +20.00% with a turnover rate of 59.71% and a net inflow of 122.929 million yuan - Sainuo Medical: +4.74% with a turnover rate of 6.99% and a net inflow of 121.228 million yuan - Mindray Medical: +0.73% with a turnover rate of 0.41% and a net inflow of 60.069 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Shutaishen: -7.52% with a net outflow of 195.891 million yuan - Zhendai Medical: +2.51% with a net outflow of 185.422 million yuan - Yatai Pharmaceutical: -5.58% with a net outflow of 164.905 million yuan [3]

Group 1 - Major focus stocks include Dayou Energy, which opened up 8.08% after 13 consecutive days of gains [1] - Bluefeng Biochemical, investing in the new energy sector, opened down 5.85% after 17 consecutive days of gains [1] - Retail stock Guoguang Chain opened up 0.22% after 8 consecutive days of gains [1] Group 2 - Low-priced stock Haiou Zhugong opened down 4.08% after 10 consecutive days of gains [1] - Maohua Shihua opened down 4.62% after 2 consecutive days of gains [1] - Robotics concept stock Ruineng Technology opened down 8.24% after 5 consecutive days of gains [1] Group 3 - Deep Earth Economy concept stock Huanghe Xuanfeng opened up 5.05% after 7 consecutive days of gains [1] - Shihua Machinery opened at the daily limit after 3 consecutive days of gains [1] - Antiviral concept stock Yatai Pharmaceutical opened up 0.26% after 7 consecutive days of gains [1] Group 4 - Chenxin Pharmaceutical opened flat after 4 consecutive days of gains [1] - Mergers and acquisitions stock Yingxin Development opened at the daily limit after 3 consecutive days of gains [1]

Market Overview - On October 22, the trading volume of the Shanghai and Shenzhen stock markets reached 1.67 trillion, a decrease of 224.8 billion compared to the previous trading day [1] - Sectors that saw significant gains included deep earth economy concepts, plant-based meat, wind power equipment, and real estate, while precious metals and battery sectors experienced declines [1] Stock Performance - High-performing stocks included Dayou Energy with 9 consecutive trading limits, *ST Nan Zhi with 9 days of gains, and *ST Wan Fang with 8 days of gains [3] - The top three net purchases on the daily leaderboard were Keri Technology, Asia-Pacific Pharmaceutical, and Marco Polo, with net purchases of 140 million, 127 million, and 90.2 million respectively [3] Institutional Activity - The top three net sales on the daily leaderboard were Hezhu Intelligent, Haima Automobile, and Deshi Co., with net sales of 118 million, 99.5 million, and 96.2 million respectively [4] - Among stocks involving institutional special seats, the top three net purchases were Rongxin Culture, Kebo Da, and Te Yi Pharmaceutical, with net purchases of 111 million, 41.7 million, and 39.1 million respectively [4] Company Highlights Keri Technology - Positioned as a provider of mid-to-late stage solutions for lithium battery manufacturing equipment, the company has seen significant growth in its XR/VR testing equipment, which has been shipped in bulk to leading clients [5] - For the first half of the year, the company reported revenue of 1.106 billion and a net profit of 123 million, with revenue growth of 6.31% and net profit growth of 37.28% year-on-year, indicating notable performance improvement [6] Asia-Pacific Pharmaceutical - Announced a change in control with the major shareholder, Fubon Group, planning to transfer 14.62% of shares to Xinghao Holdings at 8.26 yuan per share, totaling 900 million [7] - The company plans to raise up to 700 million through a private placement to fund the development of oncolytic virus drugs and long-acting complex formulations, transitioning from traditional generics to improved new drugs and innovative drugs [7] Hezhu Intelligent - Recently won a bid for the fusion energy BEST vacuum chamber project worth 209 million and is forming a specialized team to tackle core components of fusion reactors [9] - The company's color sorting machines account for 57% of its revenue, with 20-25% of this business coming from exports, maintaining a strong position in the domestic market [9] Key Trading Stocks - Rongxin Culture saw a 3.56% increase with a turnover rate of 45.97% and a total transaction volume of 809 million, with institutional net purchases of 111 million [10] - Sanwei Communication increased by 5.00% with a turnover rate of 33.08% and a total transaction volume of 3.005 billion, with institutional net purchases of 23 million [10] - Te Yi Pharmaceutical hit the daily limit with a turnover rate of 30.11% and a total transaction volume of 1.201 billion, with institutional net purchases of 39.1 million [10]

Core Insights - Asia-Pacific Pharmaceutical experienced a trading halt with a daily turnover rate of 15.80% and a transaction volume of 884 million yuan, showing a price fluctuation of 8.91% [2] - Institutional investors net bought 15.49 million yuan, while brokerage seats collectively net bought 111 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange's watchlist due to a price deviation of 10.43% [2] Trading Activity - The top five brokerage seats accounted for a total transaction volume of 238 million yuan, with a buying volume of 182 million yuan and a selling volume of 55.89 million yuan, resulting in a net purchase of 127 million yuan [2] - Among the brokerage seats, four institutional specialized seats were involved, with a total buying amount of 52.83 million yuan and a selling amount of 37.34 million yuan, leading to a net purchase of 15.49 million yuan [2] Historical Performance - Over the past six months, the stock has appeared on the watchlist 13 times, with an average price increase of 2.89% the day after being listed and an average increase of 5.60% over the following five days [2] - Today's main capital inflow for the stock was 263 million yuan, with a significant single order net inflow of 267 million yuan, while large orders saw a net outflow of 4.89 million yuan [2] - In the last five days, the main capital inflow totaled 275 million yuan [2]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

Core Viewpoint - The innovative drug sector is experiencing a significant boost, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion (approximately 81.2 billion RMB) [1][3]. Group 1: Market Reaction - On October 22, A-shares and Hong Kong stocks related to innovative drugs surged, with companies like Angli康, 哈三联, and 亚太药业 hitting the daily limit, while药捷安康 saw an increase of over 25% [1][2]. - The biopharmaceutical sector in Hong Kong also experienced substantial gains, with notable increases in stocks such as 轩竹生物 and 信达生物 [2]. Group 2: Strategic Collaboration Details - The collaboration between 信达生物 and 武田制药 aims to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including late-stage candidates IBI363 and IBI343, as well as an early-stage project IBI3001 [2][3]. - 信达生物 will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and has the potential to earn up to $10.2 billion in milestone payments [3]. Group 3: Market Trends and Future Outlook - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [4]. - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [5][6]. - The fourth quarter is expected to see an acceleration in business development (BD) activities, as large international pharmaceutical companies typically allocate their annual budgets during this period [6]. Group 4: Investment Sentiment - Analysts suggest that the current environment is favorable for innovative biotech companies, with increased liquidity and risk appetite in the Hong Kong market [7]. - The focus on innovative drug companies is expected to grow as their core pipelines are validated, while second-tier pipelines are approaching proof-of-concept data [7].

Group 1 - The core viewpoint of the news highlights a significant rise in innovative drug concept stocks, indicating positive market sentiment in this sector [1] Group 2 - Kintor Pharmaceutical saw an increase of over 10% in its stock price [1] - AngliTech experienced a rise of over 8% [1] - Other companies such as Hotgen Biotech, Asia-Pacific Pharmaceutical, and Shuyou Shen also showed upward movement in their stock prices [1]